Menu Search
Equities

Akums Drugs and Pharmaceuticals Ltd

AKUMS:NSI

Akums Drugs and Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)640.10
  • Today's Change30.45 / 4.99%
  • Shares traded35.48k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 10:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Akums Drugs and Pharmaceuticals Ltd had net income fall from a gain of 948.55m to a loss of 40.35m despite a 14.32% increase in revenues from 36.55bn to 41.78bn.
Gross margin37.76%
Net profit margin6.95%
Operating margin7.79%
Return on assets7.20%
Return on equity16.37%
Return on investment11.08%
More ▼

Cash flow in INRView more

In 2024, Akums Drugs and Pharmaceuticals Ltd increased its cash reserves by 115.18%, or 594.42m. The company earned 4.98bn from its operations for a Cash Flow Margin of 11.92%. In addition the company used 3.30bn on investing activities and also paid 1.08bn in financing cash flows.
Cash flow per share27.88
Price/Cash flow per share22.97
Book value per share185.07
Tangible book value per share184.54
More ▼

Balance sheet in INRView more

Akums Drugs and Pharmaceuticals Ltd has a Debt to Total Capital ratio of 15.71%, a lower figure than the previous year's 30.66%.
Current ratio2.13
Quick ratio1.59
Total debt/total equity0.1872
Total debt/total capital0.1571
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items dropped -104.25%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		--
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.